Who are SPM 962's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TVP-1012, Aplause®, NPC-16 Continuous Dosing Regimen Group, OPC-262, SPMC 2, NPC-16 Standard Dosing Regimen Group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/spm-962.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SPM 962 — Competitive Intelligence Brief

SPM 962 (SPM 962) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P receptor modulator. Area: Autoimmune diseases.

phase 3 S1P receptor modulator S1PR1 Autoimmune diseases Small molecule Live · refreshed every 30 min

Target snapshot

SPM 962 (SPM 962) — Otsuka Pharmaceutical Co., Ltd.. SPM 962 is a selective, high-affinity, and orally bioavailable small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SPM 962 TARGET	SPM 962	Otsuka Pharmaceutical Co., Ltd.	phase 3	S1P receptor modulator	S1PR1
TVP-1012	TVP-1012	Takeda	phase 3	S1P receptor modulator	S1PR1
Aplause®	Aplause®	Phytopharm Consulting Brazil	phase 3	S1P receptor modulator	S1PR1
NPC-16 Continuous Dosing Regimen Group	NPC-16 Continuous Dosing Regimen Group	Nobelpharma	phase 3	S1P receptor modulator	S1PR1
OPC-262	OPC-262	Kyowa Kirin Co., Ltd.	phase 3	S1PR1 inhibitor	S1PR1
SPMC 2	SPMC 2	Korea University Anam Hospital	phase 3	Sphingosine-1-phosphate receptor 1 (S1PR1) modulator	S1PR1
NPC-16 Standard Dosing Regimen Group	NPC-16 Standard Dosing Regimen Group	Nobelpharma	phase 3	S1P receptor modulator	S1PR1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P receptor modulator class)

Promius Pharma, LLC · 2 drugs in this class
Nobelpharma · 2 drugs in this class
Bausch & Lomb Incorporated · 1 drug in this class
Biogen · 1 drug in this class
Celgene · 1 drug in this class
Geropharm · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Huazhong University of Science and Technology · 1 drug in this class
Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPM 962 — Competitive Intelligence Brief. https://druglandscape.com/ci/spm-962. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab